Yeh Sylvia H, Mink ChrisAnna M
UCLA Center for Vaccine Research at Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, 1124 W. Carson Street, Torrance, CA 90502, USA.
Drugs. 2006;66(6):731-41. doi: 10.2165/00003495-200666060-00001.
Pertussis vaccination of young children has been effective in reducing the overall disease burden due to Bordetella pertussis in many countries. However, the disease has not been eliminated, although humans are the only known host of this pathogen. In fact, in some countries, the number of reported cases has increased dramatically from their nadir and epidemics routinely occur. In areas where >80% of children <2 years of age have been vaccinated, the burden of disease has shifted from elementary school-aged children (who are presumably protected by vaccination) to young infants (<6 months of age) and individuals >11 years of age. With the recent availability of acellular pertussis vaccines for older children to adults, consideration of a change in current vaccination policy is necessary in order to provide better disease control.
在许多国家,幼儿接种百日咳疫苗已有效减轻了由百日咳博德特氏菌引起的总体疾病负担。然而,尽管人类是这种病原体唯一已知的宿主,但该疾病尚未消除。事实上,在一些国家,报告病例数已从最低点急剧增加,并且疫情经常发生。在2岁以下儿童疫苗接种率超过80%的地区,疾病负担已从小学适龄儿童(据推测已通过接种疫苗得到保护)转移至小婴儿(6个月以下)和11岁以上人群。随着近期大龄儿童至成人可用无细胞百日咳疫苗的出现,有必要考虑改变当前的疫苗接种政策,以便更好地控制疾病。